Forbion — Full Portfolio

MapLight Therapeutics is a biopharmaceutical company developing targeted treatments for central nervous system disorders through a platform designed to modulate neural circuits implicated in disease.

BiotechRedwood City, US

Anatol Kreitzer(Executive Officer)Kristopher Hanson(Executive Officer)Erin Foff(Executive Officer)inJames Lillie(Executive Officer)Jonathan Gillis(Executive Officer)inVSVishwas Setia(Executive Officer)in

Board seatNanna Luneborg· per SEC Form D · $372.4M raise · filed Jul 2025

Co-investorsNONovo Holdings

Azafaros is a clinical-stage biopharmaceutical company developing small-molecule therapies for severe rare genetic metabolic disorders, including GM1/GM2 gangliosidoses, Niemann-Pick type C disease, and other conditions.

BiotechDeep TechHealthtechMedical DevicesLeiden, NL

Hans Aerts(Professor)HOHermen Overkleeft(Professor)Stan van Boeckel(Professor)

Co-investorsBIBioMedPartnersJEJeito CapitalBIBioGeneration VenturesPIPictet GroupSESeroba Life Sciences

Beacon Therapeutics develops gene therapies for patients with serious diseases that lack or have limited treatment options, including investigational products like laru-zova for genetic conditions.

BiotechDigital HealthMedical Devices

DCDaniel Chung(Chief Medical Officer)inLBLance Baldo(Chief Executive Officer)inASAbraham Scaria(Chief Scientific Officer)in

Co-investorsADAdvent Life SciencesOXOxford Science EnterprisesTCTCG Crossover

CatalYm develops immunotherapies for solid tumors by neutralizing GDF-15, a factor cancer cells use to suppress immune responses and resist treatment.

BiotechDeep TechHealthtechMunich, DE

Jörg Wischhusen(Scientific Co-founder)SCScott Clarke(Chief Executive Officer)inPGPeter Garcia(Chief Financial Officer)SRSujata Rao(Chief Medical Officer)inSRStefan Ries(Chief Scientific Officer and Head of Munich Site)inAGAndrea Goddard(Chief Technical Officer)in

Co-investorsJEJeito CapitalBIBioqube VenturesBABayern KapitalCACanaan PartnersNONovartis Venture FundBIBioGeneration Ventures+1 more

Citryll is a clinical-stage biotech developing CIT-013, an antibody therapy that targets extracellular traps by selectively binding citrullinated histones to both inhibit new trap formation and clear existing ones.

BiotechHealthtechMedical DevicesOss, NL

RCRenato Chirivi(Co-founder (former CSO))in

BoardPaul Peter Tak(Chair of the Board)

Co-investorsPUPureos BioventuresBIBioGeneration VenturesJOJohnson & Johnson Innovation – JJDCSESeventure PartnersBOBOMCUCurie Capital+1 more

Elevara Medicines is a clinical-stage biotech developing ELV001, a first-in-class once-daily oral CDK4/6 inhibitor that targets fibroblast-like synoviocytes as an add-on therapy for rheumatoid arthritis and other chronic inflammatory diseases.

BiotechHealthtechMedical DevicesLondon, GB

Emma Tinsley(Founder & former CEO (now Non-Executive Director))inMZMai-Britt Zocca(CEO)in

Co-investorsMOMonograph Capital PartnersSOSofinnova Partners

Engrail Therapeutics is a clinical-stage pharmaceutical company developing precision-targeted therapeutics for neupropsychiatric and neurodevelopmental disorders.

BiotechDigital HealthMedical DevicesSan Diego, US

Stephen(Co-founder, EVP Research & Development and Chief Development Officer)Paul Cayer(Chief Financial Officer)inVikram(President and Chief Executive Officer)Kimberly(Chief Scientific Officer)Quentin(Chief Technical Officer)

Co-investorsFOForesite CapitalLOLongwood FundNONorwest Venture PartnersRIRiverVest Venture PartnersYSYsios CapitalABabrdn plc+4 more

Expedition Therapeutics is a drug development company focused on advancing therapeutic programs in areas such as CAR-T immunotherapy and oncology.

BiotechHealthtechMedical DevicesSan Francisco, US

Yi Larson(Founder and CEO)GGGeoff Gilmartin(Chief Medical Officer)EHEric Hu(Chief Business Officer)

Co-investorsNONovo HoldingsSOSofinnova VenturesSASanofi Ventures

Gate Bioscience develops small molecule therapeutics called Molecular Gates for disease treatment.

BiotechDeep TechMedical Devices

Jordi Mata-Fink(Chief Executive Officer, Co-Founder)inRaman Talwar(Chief Technology Officer, Co-Founder)inPat Sharp(Scientific Founder)in

Co-investorsVEVersant VenturesANAndreessen HorowitzARARCH Venture PartnersGVGV (Google Ventures)

Granite Bio develops first-in-class therapeutic antibodies targeting inflammation, autoimmunity, and fibrosis for patients lacking effective treatment options.

BiotechMedical DevicesBasel, CH

PLPatrick Loustau(President and Chief Executive Officer)in

Co-investorsNONovartis Venture FundSASanofi VenturesVEVersant Ventures

Kynexis is a clinical-stage biotech developing KYN-5356, an oral small-molecule KAT-II inhibitor targeting the kynurenine pathway to improve cognition in neurological diseases.

BiotechDeep TechHealthtech

Robert Schwarcz(Scientific Co-founder)Carol Tamminga(Scientific Co-founder & Chair of the SAB)CKChrister Köhler(Founding Director)inKees Been(Chief Executive Officer)inJWJens Wendland(Chief Medical Officer)inNeil Swami(Chief Business Officer)

Co-investorsYSYsios CapitalNONovartis Venture FundSUSunstone Capital

Mestag is an immunology company developing first-in-class treatments for cancer and inflammatory diseases by leveraging novel understanding of fibroblast biology and tertiary lymphoid structures.

AI & Machine LearningBiotechDigital HealthHealthtechLondon, GB

Michael B. Brenner(Founder)Chris Buckley(Founder)MCMark Coles(Founder)inSRSoumya Raychaudhuri(Founder)DADavid A. Tuveson(Founder)SHSusan Hill(Chief Executive Officer)in

Co-investorsSVSV Health InvestorsGVGV (Google Ventures)NONorthpond Ventures

Mestag Therapeutics is an immunology company developing first-in-class agonist antibody therapies for cancer and inflammatory diseases based on fibroblast biology, and operates a RAFT platform for discovering new drug targets.

AI & Machine LearningBiotechHealthtech

SHSusan Hill(Chief Executive Officer)inMichael B. Brenner(Founder)Chris Buckley(Founder)MCMark Coles(Founder)inSoumya Raychaudhuri(Founder)David A. Tuveson(Founder)

Co-investorsGVGV (Google Ventures)JOJohnson & Johnson Innovation – JJDCNONorthpond VenturesSVSV Health InvestorsJJJJDC

OMEICOS is a biotech company developing small-molecule therapeutics based on synthetic analogues of omega-3 fatty acid derived epoxyeicosanoids (17,18-EEQ) for cardiovascular, inflammatory, and rare mitochondrial diseases.

BiotechHealthtechBerlin, DE

Robert Fischer(CEO/CSO & Co-Founder)inKUKaren Uhlmann(Vice President Operations & IP, Co-Founder)inWolf-Hagen Schunck(Co-Founder)John R. Falck(Co-Founder)

Co-investorsRERemiges Ventures, Inc.VEVesalius Biocapital Partners

Pheon Therapeutics develops targeted oncology treatments, focusing on antibody-drug conjugates (ADCs) for cancer therapy.

BiotechHealthtechMedical Devices

Co-investorsATAtlas VentureBIBiotechnology Value FundLILightspeed Venture PartnersREResearch Corporation TechnologiesTCTCG Crossover

Purespring develops genetic therapies targeting podocytes to treat renal diseases through its proprietary GlomThera platform.

BiotechDigital HealthHealthtechMedical Devices

MSMoin Saleem(Co-founder & Chief Scientific Advisor)in

Co-investorsSOSofinnova PartnersGIGilde HealthcareADAdvent Life SciencesBRBritish Patient Capital

SynOx Therapeutics develops emactuzumab, a monoclonal antibody treatment for tenosynovial giant cell tumours (TGCT) and macrophage-mediated diseases.

BiotechHealthtechMedical Devices

RBRay Barlow(Chief Executive Officer)in

Co-investorsHEHealthCapBIBioqube VenturesGIGimvMEMedicxi

AIRNA develops genetic medicines that use ADAR, a naturally occurring human protein, to precisely edit RNA and treat genetic diseases without permanently modifying DNA.

AI & Machine LearningBiotechDeep TechHealthtechStanford, US

TSThorsten Stafforst(Chairman of the Board of Directors)inKEKris ElveruminTBTodd Bazemore(Chief Executive Officer)inJin (Billy) Li(Treasurer and Secretary)inPaul Vogel(Chief Executive Officer and President)in

BoardRodger Novak(Chair)in

Co-investors+N+ND CapitalARARCH Venture PartnersVEVenrockFAFast Track InitiativeNENextech InvestNONovalis LifeSciences+2 more

BiotechHealthtechCambridge, US

James McCullough(Executive Officer, Director)William Kelly(Chief Financial Officer and Secretary of Issuer)Thomas McLain(Chief Executive Officer and Director of Issuer)Sara Barrington(Executive Officer)

BoardJoseph Boystak(Director)in

Board seatGMGeert-Jan Mulder· per SEC Form D · $2.2M raise · filed Jul 2015

Co-investorsARArcus VenturesNGNGN Capital

Milestone Pharmaceuticals is a life sciences company that develops therapies for patients with cardiovascular and other diseases.

BiotechDigital HealthHealthtechMedical DevicesMontreal, US

Ela Borenstein(Director)Francis Plat(Executive Officer)Yves Rosconi(Director)Scott Weiner(Director)Martin Maguire(Executive Officer)Philippe Douville(Executive Officer, Director)

Board seatMBMarco Boorsma· per SEC Form D · $6.9M raise · filed Jul 2017

Co-investorsPAPappas CapitalRTRTW Investments L.P.

Altesa BioSciences is a clinical-stage pharmaceutical company developing vapendavir, an orally administered antiviral targeting rhinovirus infections in patients with chronic lung diseases such as COPD and asthma.

BiotechHealthtechCollege Park, US

JCJohn Clerici(Executive Officer)inAndrew Drechsler(Executive Officer)Brett Giroir(Executive Officer, Director)

BoardNWNicholas Williams(Director)MSMoncef Slaoui(Director)JEJon Edwards(Director)in

Co-investorsGRGRA VentureMEMedicxiPIPitango

Amphista Therapeutics develops next-generation targeted protein degradation (TPD) medicines using its proprietary Targeted Glue technology, which is engineered to selectively trigger the destruction of disease-causing proteins.

BiotechCambridge, GB

LMLouise Modis(Chief Executive Officer)inMPMartin Pass(Chief Development Officer)inGBGiles Brown(Executive VP Drug Discovery)in

Co-investorsADAdvent Life SciencesNONovartis Venture FundSVSV Health InvestorsDEDementia Discovery FundEUEuropean Investment FundGIGilde Healthcare+2 more

Aneta operates an email-based AI research service that runs 15 specialized agents across academic, market, technical, and legal sources for days to produce long, citation-backed research reports.

AI & Machine LearningEnterprise SoftwareSaaS

Co-investorsPEPebblebedANAndera PartnersBGBGVFOFountain Healthcare PartnersHTHTGFPMPMV+2 more

Completed patient enrollment in its Phase 2 AURORA trial.

Co-investorsP5P53 InvestSASarsia Management ASINInvestinor

Complement Therapeutics is a clinical-stage biotechnology company developing gene therapies for complement-mediated diseases, with a lead AAV-based candidate (CTx001) for Geographic Atrophy secondary to Age-related Macular Degeneration.

BiotechDigital HealthHealthtechMedical DevicesMunich, DE

RHRafiq Hasan(CEO and Managing Director)inMAMuhammad Ali Memon(Chief Medical Officer)in

Co-investorsCACambridge Innovation CapitalHAHadean VenturesSESeroba Life SciencesBGBGVBIBioGeneration VenturesGIGimv+1 more

Coultreon is a drug discovery and development company that advances small and large molecule therapeutic programmes across various disease areas, combining disease biology expertise with technology platforms.

AI & Machine LearningBiotech

PRPierre Raboisson(Chief Executive Officer Chief Scientific Officer Co-founder)inMDMarie De Vulder(Chief Legal Officer Co-founder)inGPGuy Peeters(Chief Financial Officer Co-founder)inJGJohn-Paul Gallivan(Head of Development Co-founder)inFKFabrice Kolb(Head of Immunology Co-founder)inPieter Peeters(Operating & Technology Officer Co-founder)in

Co-investorsLOLongwood FundSOSofinnova VenturesBABAM ElevateFIFinchley Healthcare VenturesLULuma GroupNONovo Holdings+1 more

F2G develops medicines to treat serious fungal diseases where existing therapies have failed or are ineffective.

BiotechDigital HealthHealthtechMedical Devices

Co-investorsADAdvent Life SciencesAIAisling CapitalAMAMR Action FundASAstellas Venture Management LLCBRBrace PharmaSOSofinnova Partners+3 more

A venture capital firm investing in biotech companies across all stages of pharmaceutical development, and in sustainable solutions across food, agriculture, materials, and environmental technologies through its BioEconomy strategy.

AgTechBiotechCleantechClimate TechImpact & Social GoodAmsterdam, NL

Co-investorsBOBOMKFKfW Capital

Genomines uses biological systems to extract battery-grade nickel from low-grade soils, producing critical metals at lower cost and environmental impact than traditional mining.

BiotechCleantechEnergyNew MaterialsParis, FR

FKFabien Koutchekian(CEO)inDRDali Rashid(CTO)in

Co-investorsCACarbonDEDeepTech & Climate FondsENEntrepreneur FirstLOLOWERCARBONLOLowercarbon CapitalSTSTATION F+6 more

Portfolio company acquired by Novo Nordisk for $1.1B USD.

Co-investorsAMAmorChemGEGenesys CapitalJDJDRF T1D FundNENew Enterprise Associates (NEA)TATarnagulla VenturesADadMare BioInnovations+2 more

LoQus23 Therapeutics is a drug discovery company developing treatments for triplet repeat expansion diseases such as Huntington's disease, focused on preclinical CNS and neuroscience research.

BiotechDeep TechCambridge, GB

DRDavid Reynolds(Co-founder & CEO)inCBCaroline Benn(Co-founder & CSO)in

Co-investorsNONovartis Venture FundSVSV Health InvestorsDEDementia Discovery Fund

Mariana Oncology, a Novartis company, develops precision radioligand therapies that deliver radioisotopes to diseased cells while limiting effects on healthy tissue.

BiotechHealthtechMedical Devices

Co-investorsACAccess BiotechnologyATAtlas VentureNENextech InvestRARA Capital

Modern Systems Talk (MST) publishes content and insights on technology topics including system architecture, cloud computing, automation, AI, cybersecurity, and digital transformation.

Media & Entertainment

Co-investorsAGAgate Medical Investments LPSCSCP Vitalife PartnersGVGV (Google Ventures)NONorthpond VenturesSVSV Health Investors

Noema Pharma develops a late-stage portfolio of oral small molecule therapeutics for people with neurological and related disorders, targeting both orphan and larger indications with significant unmet medical needs.

BiotechHealthtechMedical Devices

ILIlise Lombardo(Chief Executive Officer)inVKVolker Knappertz(Executive Vice President of Research & Development)inMSMichael Samar(Chief Financial Officer)inRLRob Lasser(Chief Medical Officer)in

Co-investorsBIBioMedPartnersJEJeito CapitalRORoche Venture FundSOSofinnova PartnersEQEQTEQEQT Life Sciences+2 more

NovaMeat develops plant-based protein food products, positioning them as part of a new culinary tradition.

FoodTech

GSGiuseppe Scionti(Founder)in

Co-investorsAUAurum Venture PartnersCACarbonSOSofinnova PartnersUNUnovis Asset ManagementVUVU Venture PartnersRURubio Impact Ventures

Progentos develops small-molecule therapeutics to stimulate myelin regeneration in multiple sclerosis patients by activating oligodendrocyte progenitor cells.

BiotechDeep TechMedical DevicesWatertown, US

DHDmitrij Hristodorov(Director)inChristopher Loose(Executive Officer, Director)Sanjay Magavi(Executive Officer)MTMarc-Olivier Turgeon(Director)in

BoardARAleks Radovic-Moreno(Director)inDJDan Janney(Director)

Co-investorsALAlta PartnersLOLongwood FundMIMission BiocapitalSEService Provider CapitalDODolby Family Ventures

BiotechMalvern, US

Mark Lupher(Executive Officer)Dominick C. Colangelo(Executive Officer, Director)

BoardJames W. Broderick, M.D.(Director)GMGeert-Jan Mulder(Director)inJFJohn Friedman(Director)inHarold R. Werner(Director)

Co-investorsEAEaston CapitalSOSofinnova VenturesEAEaston Capital Investment Group

Protego provides chargeback management software that automates dispute processes and tracks chargebacks in real time to help merchants identify patterns in fraudulent activity and recover revenue.

CybersecurityEnterprise SoftwareSaaSBogotá, CO

PRPablo Rojas(Founder)in

Co-investorsNONovartis Venture FundY Y CombinatorGLGlilot Capital PartnersOMOmega FundsYKYK Bioventures

Protego Bio is a biotech company developing first-in-class therapies for protein misfolding diseases, including its lead candidate PROT-001 for AL amyloidosis, based on research into pharmacological chaperones.

AI & Machine LearningBiotechDeep TechDigital HealthHealthtechSan Diego, US

BJBrent J. Warner(Executive Officer, Director)inXIN JIANG(President & CEO)inHANK MICHAEL PETRASSI(Executive Officer)JEFFERY KELLY(Director)

BoardTIM LOHOFF(Director)Edward Hurwitz(Director)

Co-investorsDRDroia VenturesNONovartis Venture FundDIDigitalis VenturesLILightspeed Venture PartnersMPMPM BioImpactVIVida Ventures+1 more

RQ Bio discovers and develops long-acting monoclonal antibodies (LAAbs) targeting seasonal influenza to provide protection against severe viral disease.

BiotechHealthtech

Co-investorsFRFrazier Life SciencesLILifeArc VenturesEQEQT Life SciencesOXOxford Science EnterprisesWEWellington Management

Sidera Bio is a biotechnology company using human genetics to develop new medicines for patients.

Biotech

Co-investorsRARA CapitalNONovo Holdings

Tropic is a procurement platform that gives finance and procurement teams pricing intelligence, negotiation playbooks, and expert support to reduce spend on SaaS and AI software.

AI & Machine LearningFintechSaaSNew York City, US

JEJustin Etkin(Founder)inDCDavid Campbell(Founder)in

Co-investorsSHShine Capital